Chantix

Chantix is a brand name of varenicline, approved by the FDA in the following formulation(s):

CHANTIX (varenicline tartrate - tablet; oral)

• 
  Manufacturer: PFIZER INC
  
  Approval date: May 10, 2006
  
  Strength(s): EQ 0.5MG BASE, EQ 1MG BASE ^[RLD]

Has a generic version of Chantix been approved?

No. There is currently no therapeutically equivalent version of Chantix available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Chantix. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Aryl fused azapolycyclic compounds
  Patent 6,410,550
  Issued: June 25, 2002
  Inventor(s): Jotham Wadsworth; Coe & Paige Roanne Palmer; Brooks
  Assignee(s): Pfizer INC
  Compounds of the formula and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are defined as in the specification, intermediates in the synthesis of such compounds. pharmaceutical compositions containing such compounds and methods of using such compounds, in the treatment of neurological and psychological disorders.
  
  Patent expiration dates:
  
  
  • May 10, 2020
    
    ✓ 
    Patent use: AID TO SMOKING CESSATION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
  Patent 6,890,927
  Issued: May 10, 2005
  Inventor(s): Bogle; David E. & Rose; Peter R. & Williams; Glenn R.
  Assignee(s): Pfizer Inc
  The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene: and pharmaceutical compositions thereof. The present invention in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including two distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polymorph (referred to herein as Form C). In addition, the present invention is also directed to the D-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and the various polymorphs thereof; as well as the D,L-tartrate salt thereof and its polymorphs, and the meso-tartrate salt thereof and its polymorphs.
  
  Patent expiration dates:
  
  
  • May 6, 2022
    
    ✓ 
    Patent use: AID TO SMOKING CESSATION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0^2,11.0^4.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
  Patent 7,265,119
  Issued: September 4, 2007
  Inventor(s): Bogle; David E. & Williams; Glenn R. & Rose; Peter R.
  Assignee(s): Pfizer Inc
  The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene: and pharmaceutical compositions thereof. The present invention in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including two distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polymorph (referred to herein as Form C). In addition, the present invention is also directed to the D-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene and the various polymorphs thereof; as well as the D,L-tartrate salt thereof and its polymorphs, and the meso-tartrate salt thereof and its polymorphs.
  
  Patent expiration dates:
  
  
  • August 3, 2022
    
    ✓ 
    Patent use: AID TO SMOKING CESSATION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 10, 2011 - NEW CHEMICAL ENTITY
  
  
  • July 22, 2014 - NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE
  
  

See also...

• Chantix Consumer Information (Drugs.com)
• Chantix Consumer Information (Wolters Kluwer)
• Chantix Consumer Information (Cerner Multum)
• Chantix Advanced Consumer Information (Micromedex)
• Chantix Start Month Pak Advanced Consumer Information (Micromedex)
• Chantix AHFS DI Monographs (ASHP)
• Varenicline Consumer Information (Wolters Kluwer)
• Varenicline Consumer Information (Cerner Multum)
• Varenicline Advanced Consumer Information (Micromedex)
• Varenicline tartrate AHFS DI Monographs (ASHP)